A shot that teaches the body to clear skin tumours — even the ones it never touched

Three people with Gorlin syndrome, a genetic condition that produces basal cell carcinomas (the most common skin cancer) again and again across a lifetime, have given researchers a striking early result. Krystal Biotech's KB113 — an injection designed to make tumour tissue produce two immune signals, IL-2 and IL-12, right where they are needed — was followed by regression in more than 80% of the skin lesions doctors assessed. Most remarkably, lesions that were never injected shrank too, a sign the immune system had learned the job and was carrying it around the body. Side effects were mild to moderate and passed. The data, presented by investigator Dr. Shireen Guide at the PeDRA conference this week, are early proof-of-concept from just three patients — but for people facing surgery after surgery, a treatment that trains the body to patrol for itself is a hopeful direction.

SDG 3 · Good health and well-being — Mechanism: tech innovation